BACKGROUND: Acute respiratory viral infections are generally self-limited in healthy subjects but can lead to severe complications in immunocompromised hosts. We report the clinical impact of acute lower respiratory tract viral infections in hospitalized patients. MATERIALS AND METHODS: Of 1,001 fiberoptic bronchoscopies performed during a period of 5 years, 33 BAL samples were positive for respiratory viruses by cell culture. The main diagnosis, length of hospitalization, response to initial treatment, and the mortality rate at 30 days were analyzed. Spirometry performed before and after infection was compared in lung transplant recipients. RESULTS: The following respiratory viruses were identified in 33 cases: influenza A or B (n = 13), parainfluenza virus 1-3 (n = 7), rhinovirus (n = 5), respiratory syncytial virus (n = 4), and adenovirus (n = 4). All cases were immunocompromised patients who acquired new respiratory symptoms and/or radiologic abnormalities suggesting a pulmonary infection. Twenty-five patients (74%) did not respond to initial broad-spectrum antibiotics, and 11 patients (33%) required intensive care for respiratory failure. The overall mortality rate at 1 month was 24%. In patients with a sole viral pathogen identified in their BAL, the mortality rate was 39%. In lung transplant recipients (n = 10), the mean FEV(1) decreased from 2.2 to 1.9 L/s before and during the infection episode, respectively (p < 0.01); 3 months later, 60% of the patients had still not completely recovered to baseline values. CONCLUSION: Respiratory viruses recovered in BAL samples of immunocompromised patients are associated with severe lower respiratory complications. In lung transplant recipients, we observed a persisting impairment of pulmonary function.
BACKGROUND: Acute respiratory viral infections are generally self-limited in healthy subjects but can lead to severe complications in immunocompromised hosts. We report the clinical impact of acute lower respiratory tract viral infections in hospitalized patients. MATERIALS AND METHODS: Of 1,001 fiberoptic bronchoscopies performed during a period of 5 years, 33 BAL samples were positive for respiratory viruses by cell culture. The main diagnosis, length of hospitalization, response to initial treatment, and the mortality rate at 30 days were analyzed. Spirometry performed before and after infection was compared in lung transplant recipients. RESULTS: The following respiratory viruses were identified in 33 cases: influenza A or B (n = 13), parainfluenza virus 1-3 (n = 7), rhinovirus (n = 5), respiratory syncytial virus (n = 4), and adenovirus (n = 4). All cases were immunocompromised patients who acquired new respiratory symptoms and/or radiologic abnormalities suggesting a pulmonary infection. Twenty-five patients (74%) did not respond to initial broad-spectrum antibiotics, and 11 patients (33%) required intensive care for respiratory failure. The overall mortality rate at 1 month was 24%. In patients with a sole viral pathogen identified in their BAL, the mortality rate was 39%. In lung transplant recipients (n = 10), the mean FEV(1) decreased from 2.2 to 1.9 L/s before and during the infection episode, respectively (p < 0.01); 3 months later, 60% of the patients had still not completely recovered to baseline values. CONCLUSION:Respiratory viruses recovered in BAL samples of immunocompromised patients are associated with severe lower respiratory complications. In lung transplant recipients, we observed a persisting impairment of pulmonary function.
Authors: S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2011-08-19 Impact factor: 3.119
Authors: Kaharu C Sumino; Michael J Walter; Cassandra L Mikols; Samantha A Thompson; Monique Gaudreault-Keener; Max Q Arens; Eugene Agapov; David Hormozdi; Anne M Gaynor; Michael J Holtzman; Gregory A Storch Journal: Thorax Date: 2010-07 Impact factor: 9.139
Authors: J C Young; C Chehoud; K Bittinger; A Bailey; J M Diamond; E Cantu; A R Haas; A Abbas; L Frye; J D Christie; F D Bushman; R G Collman Journal: Am J Transplant Date: 2014-11-17 Impact factor: 8.086
Authors: Michael A Hoffman; LeeAnne M Thorson; John E Vickman; Joseph S Anderson; Nathan A May; Michelle N Schweitzer Journal: J Virol Date: 2006-06 Impact factor: 5.103
Authors: Stuart C Sweet; Hyunsook Chin; Carol Conrad; Don Hayes; Peter S Heeger; Albert Faro; Samuel Goldfarb; Ernestina Melicoff-Portillo; Thalachallour Mohanakumar; Jonah Odim; Marc Schecter; Gregory A Storch; Gary Visner; Nikki M Williams; Karen Kesler; Lara Danziger-Isakov Journal: Am J Transplant Date: 2019-07-25 Impact factor: 8.086
Authors: Yi-Wei Tang; Kristin S Lowery; Alexandra Valsamakis; Virginia C Schaefer; James D Chappell; Jill White-Abell; Criziel D Quinn; Haijing Li; Cicely A Washington; Jenna Cromwell; Chantel M Giamanco; Michael Forman; Jeffery Holden; Richard E Rothman; Michelle L Parker; Elaine V Ortenberg; Lei Zhang; Yea-Lin Lin; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2012-10-17 Impact factor: 5.948
Authors: David K Meyerholz; Branka Grubor; Jack M Gallup; Howard D Lehmkuhl; Richard D Anderson; Tatjana Lazic; Mark R Ackermann Journal: J Clin Microbiol Date: 2004-10 Impact factor: 5.948
Authors: David M Sayah; Jonathan L Koff; Lorriana E Leard; Steven R Hays; Jeffrey A Golden; Jonathan P Singer Journal: Clin Transplant Date: 2012-12-30 Impact factor: 2.863
Authors: Robin Brittain-Long; Johan Westin; Sigvard Olofsson; Magnus Lindh; Lars-Magnus Andersson Journal: BMC Med Date: 2011-04-26 Impact factor: 8.775